Related Experiment Video

Updated: Jul 17, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma

Alexander Huether1, Michael Höpfner, Viola Baradari

  • 1Institute of Physiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Biochemical Pharmacology
|February 3, 2007
PubMed
Abstract

Insights

Sorafenib effectively suppresses cholangiocarcinoma (CC) cell growth by inhibiting the MAPK pathway and inducing apoptosis. Combinations with doxorubicin or IGF-1R inhibition show promise, warranting further clinical investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Advanced cholangiocarcinoma (CC) lacks effective treatments, necessitating novel therapeutic strategies.
  • The mitogen-activated protein kinase (MAPK) pathway is frequently dysregulated in CC, promoting tumor proliferation.
  • Sorafenib, a multi-kinase inhibitor, shows anti-cancer potential but its efficacy in CC requires investigation.

Purpose of the Study:

  • To evaluate the antineoplastic effects of sorafenib on human CC cells.
  • To assess the efficacy of sorafenib in combination with conventional chemotherapeutics or IGF-1R inhibition.

Main Methods:

  • Human CC cell lines (EGI-1, TFK-1) were treated with sorafenib alone and in combination.
  • Cell proliferation, cell cycle progression, and apoptosis were analyzed.
  • Western blotting was used to assess protein expression related to cell cycle regulation.

Main Results:

  • Sorafenib inhibited MAPK pathway activation and dose-dependently suppressed CC cell proliferation.
  • Mechanisms included G(1)/G(0) cell cycle arrest and apoptosis induction, linked to p27(Kip1) upregulation and cyclin D1 downregulation.
  • Combinations of sorafenib with doxorubicin or IGF-1R inhibition yielded additive or supra-additive antiproliferative effects.
  • Sorafenib diminished the efficacy of 5-FU and gemcitabine.

Conclusions:

  • Sorafenib demonstrates potent anti-proliferative activity against human CC cells.
  • Specific combination therapies, such as with doxorubicin or IGF-1R inhibitors, enhance sorafenib's efficacy.
  • These findings support further evaluation of sorafenib in preclinical and clinical settings for CC treatment.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...